PE20221788A1 - Composiciones de proteina anti-vegf y metodos para producir la misma - Google Patents

Composiciones de proteina anti-vegf y metodos para producir la misma

Info

Publication number
PE20221788A1
PE20221788A1 PE2022001022A PE2022001022A PE20221788A1 PE 20221788 A1 PE20221788 A1 PE 20221788A1 PE 2022001022 A PE2022001022 A PE 2022001022A PE 2022001022 A PE2022001022 A PE 2022001022A PE 20221788 A1 PE20221788 A1 PE 20221788A1
Authority
PE
Peru
Prior art keywords
host cell
aflibercept
seq
methods
producing
Prior art date
Application number
PE2022001022A
Other languages
English (en)
Inventor
Shawn Lawrence
Amy Johnson
Meghan Casey
Jaimie Mastrogiacomo
Shunhai Wang
Ning Li
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=76210828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20221788(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PE20221788A1 publication Critical patent/PE20221788A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0031—Serum-free culture media
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21004—Trypsin (3.4.21.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/80—Fraction collectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2529/00—Culture process characterised by the use of electromagnetic stimulation
    • C12N2529/10—Stimulation by light
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

Referida a composiciones de proteina anti-VEGF y metodos para producir aflibercept en un medio quimicamente definido (CDM) a partir de una celula hospedera seleccionada del grupo conformado por CHO, NS0, Sp2/0, celulas renales embrionicas y BHK. Dichos metodos comprenden: (a) proporcionar la celula hospedera disenada por ingenieria genetica para expresar aflibercept; (b) cultivar la celula hospedera en medio CDM, bajo condiciones adecuadas y concentraciones acumulativas de niquel (? 0,4 µM), fierro (? 55.0 µM), cobre (? 0.8 µM), zinc (? 56.0 µM), cisteina (? 10.0 mM) y de antioxidantes como hipotaurina, hidrocortisona, entre otros (? 30,0 mM); y (c) recolectar el aflibercept producido por dicha celula hospedera. Asimismo, refiere que la cosecha resultante tiene un color no mas amarillo-marron que el Estandar Europeo de Color BY2; y por la cual se obtienen una o mas variantes de aflibercept a una concentracion de 5,0 g/L, que presentan secuencias de aminoacidos seleccionadas de los grupos SEQ ID NO.: 17, SEQ ID NO.: 18, SEQ ID NO.: 19, entre otros, y al menos un residuo oxidado de histidina y/o triptofano, o una concentracion de estos.
PE2022001022A 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma PE20221788A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962944635P 2019-12-06 2019-12-06
US202063065012P 2020-08-13 2020-08-13
PCT/US2020/046823 WO2021112924A1 (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same

Publications (1)

Publication Number Publication Date
PE20221788A1 true PE20221788A1 (es) 2022-11-25

Family

ID=76210828

Family Applications (6)

Application Number Title Priority Date Filing Date
PE2022001020A PE20221770A1 (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma
PE2022001022A PE20221788A1 (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma
PE2022001025A PE20221790A1 (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma
PE2022001026A PE20221791A1 (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma
PE2022001024A PE20221261A1 (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma
PE2022001023A PE20221789A1 (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2022001020A PE20221770A1 (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma

Family Applications After (4)

Application Number Title Priority Date Filing Date
PE2022001025A PE20221790A1 (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma
PE2022001026A PE20221791A1 (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma
PE2022001024A PE20221261A1 (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma
PE2022001023A PE20221789A1 (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma

Country Status (18)

Country Link
US (31) US11098112B2 (es)
EP (6) EP3931303A1 (es)
JP (11) JP2022552052A (es)
KR (12) KR20230051296A (es)
CN (6) CN114206907A (es)
AU (12) AU2020396490C1 (es)
BR (5) BR112021025438A2 (es)
CA (4) CA3129193C (es)
CO (6) CO2021018234A2 (es)
IL (16) IL288360B2 (es)
MX (10) MX2022006759A (es)
MY (12) MY190623A (es)
NZ (6) NZ781142A (es)
PE (6) PE20221770A1 (es)
SG (6) SG11202110958QA (es)
TW (6) TW202134256A (es)
WO (7) WO2021112929A1 (es)
ZA (3) ZA202107647B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022552052A (ja) * 2019-12-06 2022-12-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｖｅｇｆタンパク質組成物及びその製造方法
WO2022234412A1 (en) 2021-05-03 2022-11-10 Lupin Limited A process for purification of fc-fusion proteins
TW202326138A (zh) * 2021-09-08 2023-07-01 美商再生元醫藥公司 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
WO2023137143A1 (en) * 2022-01-14 2023-07-20 Shattuck Labs, Inc. Methods of contaminant removal from protein isolates
WO2023230486A2 (en) * 2022-05-23 2023-11-30 Inhalon Biopharma, Inc. Compositions and methods for inhalable therapeutics
WO2024114799A1 (zh) * 2022-12-01 2024-06-06 信达生物制药(苏州)有限公司 三特异性融合蛋白及其用途

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1522343A (en) 1923-05-02 1925-01-06 Thom Clarence Magnetic separator
US4534972A (en) 1983-03-29 1985-08-13 Miles Laboratories, Inc. Protein compositions substantially free from infectious agents
EP0283942B1 (en) 1987-03-24 1992-05-20 W.R. Grace & Co.-Conn. Basal nutrient medium for cell culture
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
WO1996006641A1 (en) * 1994-08-29 1996-03-07 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
EP2243827B2 (en) 1996-08-30 2017-11-22 Life Technologies Corporation Serum-free mammalian cell culture medium, and uses thereof
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
SE519827C2 (sv) 1998-03-30 2003-04-15 Viranative Ab Näringsmedium innehållande metionin samt användning av detta
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
ATE417928T1 (de) * 1999-06-08 2009-01-15 Regeneron Pharma Vegf-rezeptorchimären zur behandlung von augenkrankheiten, welche durch vaskuläre permeabilität charakterisiert sind.
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
WO2001039793A2 (en) * 1999-11-30 2001-06-07 Smithkline Beecham P.L.C. Pharmaceutical compositions containing sema7a polypeptides
AU6346601A (en) 2000-05-26 2001-12-11 Bristol Myers Squibb Co Soluble ctla4 mutant molecules and uses thereof
ATE420945T1 (de) 2001-02-15 2009-01-15 Centocor Inc Chemisch definiertes medium für kultivierte säugerzellen
IL158328A0 (en) 2001-04-13 2004-05-12 Wyeth Corp Surface proteins of streptococcus pyogenes
EP1404813A4 (en) 2001-06-13 2004-11-24 Genentech Inc METHOD FOR CULTIVATING ANIMAL CELLS AND POLYPEPTIDE PRODUCTION IN ANIMAL CELLS
GB0130228D0 (en) 2001-12-18 2002-02-06 Hansa Medica Ab Protein
US8777906B1 (en) 2002-01-24 2014-07-15 Robin Scott Gray Syringe with inspection window
US7332303B2 (en) 2002-12-23 2008-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
CN100537751C (zh) 2004-05-12 2009-09-09 华东理工大学 一种适合中国仓鼠卵巢细胞培养的无血清培养基
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
EP1812557A4 (en) 2004-10-29 2009-11-04 Centocor Ortho Biotech Inc COMPOSITIONS OF CHEMICALLY DEFINED MEDIA
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
US7303748B2 (en) 2005-02-02 2007-12-04 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
EP2586459B1 (en) 2005-03-25 2017-05-24 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations
WO2006131347A2 (en) * 2005-06-09 2006-12-14 Hansa Medical Ab Use of the ides proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection
GB0511769D0 (en) * 2005-06-09 2005-07-20 Hansa Medical Ab Treatment
CN1778903A (zh) 2005-09-29 2006-05-31 华东理工大学 一种动物细胞高密度连续灌注培养方法
DK2522717T3 (da) 2006-01-04 2014-04-22 Baxter Int Oligopeptid-frie cellekulturmedier
CN100502945C (zh) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
HUE053612T2 (hu) 2006-06-16 2021-07-28 Regeneron Pharma Intravitreális bevitelre alkalmas VEGF-antagonista készítmények
PT2041270E (pt) 2006-07-13 2013-12-27 Wyeth Llc Produção de glicoproteínas
UA99263C2 (ru) * 2006-08-28 2012-08-10 Арес Трейдинг С.А. СПОСОБ ОЧИСТКИ Fc-СЛИТОГО БЕЛКА
WO2008028686A2 (en) 2006-09-10 2008-03-13 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
MX2009002748A (es) 2006-09-13 2009-03-26 Abbott Lab Mejoras de cultivos celulares.
US10259860B2 (en) 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
CA2682738A1 (en) 2007-04-16 2008-10-23 Momenta Pharmaceuticals, Inc. Defined glycoprotein products and related methods
US20100221823A1 (en) 2007-06-11 2010-09-02 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
KR20100038235A (ko) 2007-08-31 2010-04-13 에프. 호프만-라 로슈 아게 글리코실화 프로파일 분석
WO2009080278A1 (en) * 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Stability testing of antibodies
JP5531295B2 (ja) 2008-07-31 2014-06-25 国立大学法人京都大学 不飽和ポリエステル樹脂とミクロフィブリル化植物繊維を含有する成形材料
AU2009296708A1 (en) 2008-09-26 2010-04-01 Merck Sharp & Dohme Corp. High titer antibody production
EP2435577A4 (en) 2009-05-26 2016-04-13 Momenta Pharmaceuticals Inc GLYCOPROTEIN PRODUCTION
KR101747103B1 (ko) 2009-06-26 2017-06-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
IN2012DN00801A (es) 2009-07-31 2015-06-26 Baxter Int
HUE053489T2 (hu) * 2009-10-20 2021-06-28 Abbvie Inc Az anti-il-13 antitestek izolálása és tisztítása a protein A affinitás kromatográviával
EP2325296A1 (en) 2009-11-20 2011-05-25 LEK Pharmaceuticals d.d. Production of glycoproteins with low N-glycolylneuraminic acid (Neu5Gc) content
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
KR20180023015A (ko) 2011-01-13 2018-03-06 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
CN102653729B (zh) 2011-03-04 2014-07-16 上海赛金生物医药有限公司 一种用于中国仓鼠卵巢细胞的培养基
WO2012140487A1 (en) 2011-04-11 2012-10-18 Cellcura Asa Protein-free culture media products for manufacturing viral-based vaccines
CN104024423B (zh) 2011-04-29 2017-03-15 拜康研究有限公司 用于降低抗体异质性的方法和产生其抗体的方法
RU2592680C2 (ru) 2011-04-29 2016-07-27 Биокон Рисерч Лимитед Способ снижения накопления лактата при культивировании и способ получения антитела
SG185920A1 (en) 2011-05-27 2012-12-28 Abbott Biotherapeutics Corp Dac hyp compositions and methods
WO2013028330A2 (en) 2011-08-19 2013-02-28 Emd Millipore Corporation Methods of reducing level of one of more impurities in a sample during protein purification
WO2013054250A1 (en) * 2011-10-10 2013-04-18 Dr Reddy's Laboratories Limited Purification method
US9364542B2 (en) 2011-10-28 2016-06-14 Excelse Bio, Inc. Protein formulations containing amino acids
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
CN102757496B (zh) * 2012-06-07 2014-06-18 山东泉港药业有限公司 一种抗vegf抗体片段的纯化制备方法
DE202012011016U1 (de) * 2012-07-03 2012-11-28 Novartis Ag Aflibercept-Spritze
WO2014015098A1 (en) * 2012-07-18 2014-01-23 Siemens Healthcare Diagnostics Inc. A method of normalizing biological samples
JP2015526430A (ja) 2012-08-02 2015-09-10 サノフイ アフリベルセプトまたはｚｉｖ−アフリベルセプトを含む製造物品
CA2883272A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
EP2722673B1 (en) * 2012-10-17 2017-07-12 Hexal AG Improved method of mapping glycans of glycoproteins
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US20140271622A1 (en) 2013-03-14 2014-09-18 Momenta Pharmaceuticals, Inc. Methods of cell culture
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
CN103146648A (zh) 2013-03-14 2013-06-12 北京京蒙高科干细胞技术有限公司 一种无动物源的淋巴细胞无血清培养基
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
SG10201912621TA (en) * 2013-03-15 2020-02-27 Genentech Inc Cell culture compositions with antioxidants and methods for polypeptide production
PT3611180T (pt) * 2013-03-15 2022-03-15 Biomolecular Holdings Llc Imunoglobulina híbrida que contém uma ligação não peptídica
CN103773732B (zh) 2013-06-08 2016-05-11 李锋 一种化学成分确定的培养基、其应用及大规模培养哺乳动物细胞的生产工艺
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015058369A1 (en) 2013-10-23 2015-04-30 Sanofi (China) Investment Co., Ltd. Use of aflibercept and docetaxel for the treatment of nasopharyngeal carcinoma
JP6609561B2 (ja) 2014-02-04 2019-11-20 バイオジェン・エムエイ・インコーポレイテッド 翻訳後修飾を濃縮するための、フロースルーモードにおける陽イオン交換クロマトグラフィーの使用
CN104073464A (zh) 2014-07-08 2014-10-01 西藏天虹科技股份有限责任公司 一种cho细胞无血清培养基及其制备方法
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
CN107428817B (zh) * 2015-03-12 2022-07-12 免疫医疗有限责任公司 纯化白蛋白融合蛋白的方法
KR101867134B1 (ko) 2015-03-23 2018-06-12 한양대학교 산학협력단 포유류 세포를 이용하여 목적 물질을 고효율로 생산하기 위한 세포 배양 배지, 이를 이용한 세포 배양 방법 및 목적 물질의 생산 방법
SG11201705743YA (en) 2015-04-01 2017-08-30 Boehringer Ingelheim Int Cell culture medium
CN105002242A (zh) 2015-07-23 2015-10-28 苏州康聚生物科技有限公司 用于cho细胞中高效表达重组人促甲状腺激素的无血清培养基及其应用
TW202340452A (zh) * 2015-08-04 2023-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
JP2018525389A (ja) 2015-08-12 2018-09-06 ノバルティス アーゲー 眼障害を治療する方法
EP3375873A4 (en) * 2015-10-22 2019-05-22 Protenova Co., Ltd. POLYPEPTIDE BINDING TO IMMUNOBLOBULINS
EP3377100A1 (en) * 2015-11-18 2018-09-26 Formycon AG Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
JP2019501687A (ja) 2015-11-18 2019-01-24 フォーマイコン アーゲーＦｏｒｍｙｃｏｎ Ａｇ Ｖｅｇｆ拮抗薬を収容したプレフィルドプラスチックシリンジ
CN105368808B (zh) * 2015-11-30 2019-04-30 苏州康聚生物科技有限公司 一种IdeS蛋白酶、其制备方法及应用
EA201891495A1 (ru) 2015-12-22 2018-11-30 Ридженерон Фармасьютикалз, Инк. Биспецифические анти-cd20/анти-cd3 антитела для лечения острого лимфобластного лейкоза
HUE063377T2 (hu) 2015-12-22 2024-01-28 Regeneron Pharma Anti-PD-1 antitestek és bispecifikus anti-CD20/anti-CD3 antitestek kombinációja a rák kezelésére
EP3196646B1 (en) * 2016-01-19 2019-12-18 Hexal AG Methods of mapping protein variants
JP6953433B2 (ja) 2016-01-26 2021-10-27 フォーマイコン アーゲーＦｏｒｍｙｃｏｎ Ａｇ Ｖｅｇｆアンタゴニストを含む液体医薬組成物および同医薬組成物を含有する充填済みシリンジ
WO2017168296A1 (en) * 2016-03-29 2017-10-05 Navya Biologicals Pvt. Ltd A process for purification of fc-fusion proteins
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
CN106279412A (zh) * 2016-09-12 2017-01-04 广东东阳光药业有限公司 一种抗vegf类单克隆抗体的纯化方法
SG10202102617QA (en) 2016-09-23 2021-04-29 Regeneron Pharma Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
LT3515946T (lt) 2016-09-23 2022-08-10 Regeneron Pharmaceuticals, Inc. Anti-muc16 (mucin 16) antikūnai
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
CN116327963A (zh) 2016-11-21 2023-06-27 济世-伊沃泰克生物制品有限公司 一种眼科制剂及其用途
PE20191436A1 (es) * 2016-12-23 2019-10-14 Serum Institute Of India Pvt Ltd Metodos mejorados para estimular la productividad de anticuerpos en el cultivo de celulas de mamiferos y reducir la agregacion durante los procesos de formulacion post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
US10941178B2 (en) * 2017-03-17 2021-03-09 Gilead Sciences, Inc. Method of purifying an antibody
KR101861163B1 (ko) 2017-04-26 2018-05-25 삼천당제약주식회사 안과용 약학 조성물
US20210228738A1 (en) * 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
KR102578087B1 (ko) * 2017-08-17 2023-09-18 저스트-에보텍 바이오로직스, 아이엔씨. 숙주세포 갈렉틴(galectins) 및 다른 오염물(contaminant)로부터 글리코실화 단백질을 정제하는 방법
AU2018350990A1 (en) * 2017-10-18 2020-05-21 Regenxbio Inc. Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap
US20210170029A1 (en) * 2017-11-20 2021-06-10 Just-Evotec Biologies, Inc. Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
CN109929027B (zh) * 2017-12-15 2020-10-09 山东博安生物技术有限公司 采用线性洗脱步骤的重组融合蛋白纯化方法
CN109929038B (zh) * 2017-12-15 2020-10-09 山东博安生物技术有限公司 Vegf捕获剂融合蛋白的纯化方法
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
EP3761953A1 (en) * 2018-03-08 2021-01-13 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
WO2019178151A1 (en) * 2018-03-13 2019-09-19 Amgen Inc. Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
CN116585466A (zh) 2018-05-10 2023-08-15 瑞泽恩制药公司 含有高浓度vegf受体融合蛋白的制剂
WO2020102740A2 (en) * 2018-11-16 2020-05-22 Spark Therapeutics, Inc. Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
CA3127228A1 (en) * 2019-01-30 2020-08-06 Amgen Inc. Aflibercept attributes and methods of characterizing and modifying thereof
EP3969564A1 (en) 2019-05-16 2022-03-23 Formycon AG Method for reducing methionine oxidation in recombinant proteins
KR102286892B1 (ko) * 2019-07-08 2021-08-06 삼천당제약주식회사 안과용 단백질 제제의 정제방법
JP2022552052A (ja) * 2019-12-06 2022-12-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｖｅｇｆタンパク質組成物及びその製造方法

Also Published As

Publication number Publication date
US11299532B2 (en) 2022-04-12
IL288360B1 (en) 2023-05-01
US20220048975A1 (en) 2022-02-17
US20240067701A1 (en) 2024-02-29
KR20220038347A (ko) 2022-03-28
AU2023201590A1 (en) 2023-04-13
PE20221261A1 (es) 2022-08-16
KR20230152810A (ko) 2023-11-03
JP2022552052A (ja) 2022-12-15
BR112022001016A2 (pt) 2022-08-16
MY190627A (en) 2022-04-27
IL288352B (en) 2022-11-01
MY190624A (en) 2022-04-27
WO2021112923A1 (en) 2021-06-10
US20210171570A1 (en) 2021-06-10
IL296512B2 (en) 2023-12-01
EP3931204A1 (en) 2022-01-05
CN114401994A (zh) 2022-04-26
JP2022548818A (ja) 2022-11-22
IL288367A (en) 2022-01-01
US11407813B2 (en) 2022-08-09
KR102519234B1 (ko) 2023-04-10
US20230041349A1 (en) 2023-02-09
IL288367B (en) 2022-10-01
AU2020397865C1 (en) 2023-04-27
US20210214430A1 (en) 2021-07-15
US20230235019A1 (en) 2023-07-27
US11535663B2 (en) 2022-12-27
AU2020397803B2 (en) 2022-12-15
TW202134256A (zh) 2021-09-16
MX2022012042A (es) 2022-10-27
AU2020397865A1 (en) 2021-10-28
KR20220041083A (ko) 2022-03-31
KR20240005206A (ko) 2024-01-11
TW202128745A (zh) 2021-08-01
CO2021018234A2 (es) 2022-01-17
IL302538A (en) 2023-07-01
JP2022547651A (ja) 2022-11-15
US20210214733A1 (en) 2021-07-15
US20220033472A1 (en) 2022-02-03
MX2023014077A (es) 2023-12-11
BR112021025359A2 (pt) 2022-06-21
US20220162289A1 (en) 2022-05-26
NZ781143A (en) 2023-05-26
AU2020398125B2 (en) 2022-12-15
US11186625B2 (en) 2021-11-30
CA3159586A1 (en) 2021-06-10
US20220227836A1 (en) 2022-07-21
US11098112B2 (en) 2021-08-24
WO2021112928A1 (en) 2021-06-10
CA3172625A1 (en) 2021-06-10
IL288360B2 (en) 2023-09-01
JP2024026116A (ja) 2024-02-28
EP3906302A1 (en) 2021-11-10
AU2020398125C1 (en) 2023-05-11
IL288360A (en) 2022-01-01
US11958894B2 (en) 2024-04-16
IL288357A (en) 2022-01-01
AU2020398125A1 (en) 2021-10-28
US12012444B2 (en) 2024-06-18
US20210371501A1 (en) 2021-12-02
US20230068199A1 (en) 2023-03-02
AU2020398547A1 (en) 2021-10-28
BR112021025158A2 (pt) 2022-06-21
ZA202107644B (en) 2022-03-30
IL309560A (en) 2024-02-01
IL296864B2 (en) 2023-10-01
AU2023201589A1 (en) 2023-04-06
US11649273B2 (en) 2023-05-16
US20210171605A1 (en) 2021-06-10
KR20230051296A (ko) 2023-04-17
MY190626A (en) 2022-04-27
KR102519236B1 (ko) 2023-04-10
SG11202110968VA (en) 2021-10-28
PE20221790A1 (es) 2022-11-25
US11505594B2 (en) 2022-11-22
IL301888A (en) 2023-06-01
SG11202110958QA (en) 2021-10-28
US11485770B2 (en) 2022-11-01
TW202122417A (zh) 2021-06-16
BR112021025438A2 (pt) 2022-06-21
US20210206833A1 (en) 2021-07-08
CA3129193A1 (en) 2021-06-10
CO2021018214A2 (es) 2022-01-17
MX2022006758A (es) 2023-01-30
IL288351B1 (en) 2024-01-01
AU2020398547B2 (en) 2022-12-22
CN114206914A (zh) 2022-03-18
WO2021112927A1 (en) 2021-06-10
US11542317B1 (en) 2023-01-03
NZ781145A (en) 2023-05-26
MX2021014862A (es) 2022-09-27
IL288352B2 (en) 2023-03-01
IL288351B2 (en) 2024-05-01
IL288355B (en) 2022-11-01
CN114206925A (zh) 2022-03-18
MX2021014863A (es) 2022-09-28
WO2021112924A1 (en) 2021-06-10
MX2022006760A (es) 2023-01-30
AU2020398830A1 (en) 2021-10-28
AU2020396490B2 (en) 2022-12-15
US20220009998A1 (en) 2022-01-13
US20220235116A1 (en) 2022-07-28
AU2020397803A1 (en) 2021-10-28
PE20221789A1 (es) 2022-11-25
BR112021025432A2 (pt) 2022-06-21
US20220127331A1 (en) 2022-04-28
US11174283B2 (en) 2021-11-16
IL309491A (en) 2024-02-01
US11505593B2 (en) 2022-11-22
IL296893B2 (en) 2024-05-01
US20220227835A1 (en) 2022-07-21
US20230119662A1 (en) 2023-04-20
EP3906303A1 (en) 2021-11-10
JP2024009949A (ja) 2024-01-23
IL296863A (en) 2022-11-01
CA3129193C (en) 2022-10-04
IL288355B2 (en) 2023-03-01
IL296864A (en) 2022-11-01
IL296893A (en) 2022-12-01
US11753459B2 (en) 2023-09-12
AU2020398830C1 (en) 2023-04-27
IL296512A (en) 2022-11-01
NZ781142A (en) 2023-05-26
US11104715B2 (en) 2021-08-31
TW202128744A (zh) 2021-08-01
MY193353A (en) 2022-10-06
SG11202110964QA (en) 2021-10-28
MX2022011973A (es) 2022-11-09
KR20240007293A (ko) 2024-01-16
US20230331812A1 (en) 2023-10-19
NZ781138A (en) 2023-05-26
US20220389081A1 (en) 2022-12-08
EP3931303A1 (en) 2022-01-05
IL288357B2 (en) 2023-03-01
SG11202110972UA (en) 2021-10-28
CO2021018192A2 (es) 2022-01-17
MX2022006788A (es) 2022-07-11
CN114206924A (zh) 2022-03-18
NZ781136A (en) 2023-05-26
EP3906249A1 (en) 2021-11-10
US11472861B2 (en) 2022-10-18
US20220033471A1 (en) 2022-02-03
AU2023201588A1 (en) 2023-04-13
IL302921A (en) 2023-07-01
MX2023005421A (es) 2023-05-23
US11732025B2 (en) 2023-08-22
AU2023201585A1 (en) 2023-04-13
IL296893B1 (en) 2024-01-01
IL296863B2 (en) 2023-10-01
KR20240005222A (ko) 2024-01-11
WO2021112925A1 (en) 2021-06-10
AU2020397803C1 (en) 2023-05-11
MY193350A (en) 2022-10-06
KR102619866B1 (ko) 2024-01-04
IL288352A (en) 2022-01-01
IL288357B (en) 2022-11-01
IL304390A (en) 2023-09-01
CO2021018181A2 (es) 2022-01-17
AU2020396490C1 (en) 2023-04-27
KR20220038348A (ko) 2022-03-28
AU2020396490A1 (en) 2021-10-28
CN114423783A (zh) 2022-04-29
CA3172631A1 (en) 2021-06-10
MY190625A (en) 2022-04-27
KR20220038349A (ko) 2022-03-28
US11053280B2 (en) 2021-07-06
EP3906250A1 (en) 2021-11-10
CO2021018203A2 (es) 2022-01-17
KR20220038062A (ko) 2022-03-25
IL288351A (en) 2022-01-01
WO2021112929A1 (en) 2021-06-10
US20220275054A1 (en) 2022-09-01
KR20220035393A (ko) 2022-03-22
SG11202110953UA (en) 2021-10-28
MY190623A (en) 2022-04-27
NZ781137A (en) 2023-05-26
PE20221791A1 (es) 2022-11-25
US20220009997A1 (en) 2022-01-13
JP2022547652A (ja) 2022-11-15
MY193349A (en) 2022-10-06
IL288355A (en) 2022-01-01
CO2022000660A2 (es) 2022-01-28
TW202128743A (zh) 2021-08-01
US20230272044A1 (en) 2023-08-31
AU2023201748A1 (en) 2023-06-01
US20220009999A1 (en) 2022-01-13
MX2022006759A (es) 2023-01-30
US20220098280A1 (en) 2022-03-31
US20220396608A1 (en) 2022-12-15
AU2020398830B2 (en) 2022-12-15
IL296863B1 (en) 2023-06-01
US20210206832A1 (en) 2021-07-08
AU2020397865B2 (en) 2022-12-15
CN114206907A (zh) 2022-03-18
IL296864B1 (en) 2023-06-01
SG11202110955VA (en) 2021-10-28
ZA202107647B (en) 2022-03-30
PE20221770A1 (es) 2022-11-11
TW202128991A (zh) 2021-08-01
US11459374B2 (en) 2022-10-04
US11306135B2 (en) 2022-04-19
BR112021025769A2 (pt) 2022-04-12
US11459373B2 (en) 2022-10-04
US20210284684A1 (en) 2021-09-16
CA3172631C (en) 2024-01-02
MY193351A (en) 2022-10-06
MY193355A (en) 2022-10-06
AU2023201586A1 (en) 2023-04-13
JP2022548197A (ja) 2022-11-17
US20230357357A1 (en) 2023-11-09
MY190686A (en) 2022-05-10
JP2023171771A (ja) 2023-12-05
AU2020398547C1 (en) 2023-05-11
US11440950B2 (en) 2022-09-13
US11286290B2 (en) 2022-03-29
US11548932B2 (en) 2023-01-10
MY193354A (en) 2022-10-06
KR20230051297A (ko) 2023-04-17
WO2021112926A1 (en) 2021-06-10
JP2023179531A (ja) 2023-12-19
US12012445B2 (en) 2024-06-18
IL296512B1 (en) 2023-08-01
US11180540B2 (en) 2021-11-23
US11098311B2 (en) 2021-08-24
ZA202107646B (en) 2022-03-30
JP2024009950A (ja) 2024-01-23
JP2022550930A (ja) 2022-12-06
IL288367B2 (en) 2023-02-01

Similar Documents

Publication Publication Date Title
PE20221788A1 (es) Composiciones de proteina anti-vegf y metodos para producir la misma
AR063683A1 (es) Anticuerpos para il-17a
ES2579602T3 (es) Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de uso de estos
PE20190108A1 (es) Moleculas de anticuerpo para el tratamiento del cancer
RU2013122843A (ru) Гликоформы антитела против фолатного рецептора альфа
PE20211500A1 (es) Anticuerpos dirigidos contra il-11ra
ES2692918T3 (es) Métodos y composiciones para producir aldehídos grasos
CL2011000632A1 (es) Anticuerpo humanizado anti-receptor de interleuquina 6 (il-6); regiones variables y cadenas pesadas o livianas de los mismos; secuencia nucleotídica que lo codifica; vector; célula huésped; método de producción; y composición farmacéutica que lo comprende.
AR065420A1 (es) Anticuerpos anti-il-23 p19 de ingenieria
AR065286A1 (es) Composiciones y metodos que utilizan arn de interferencia destinado a genes de tipo mthfr para el control de nematodos
AR050095A1 (es) Secuencias de subinidades pequenas de sintasa acetohidroxiacida de monocotiledoneas y metodos de uso.
AR072967A1 (es) Polipeptidos del factor de estimulacion de la colonia de granulocitos bovino (bg-csf) modificados y sus usos
CO6241166A2 (es) Metodos de produccion de proteinas utilizando compuestos anti-senectud
HRP20200899T1 (hr) Neljudske životinje koje imaju humanizirane fc-gamma receptore
RU2016123135A (ru) Отличные от человека животные, содержащие гуманизированный ген индуцирующего пролиферацию лиганда
AR054788A1 (es) Genes de senalizacion celular y metodos relacionados con los mismos
RU2016123708A (ru) Отличные от человека животные, содержащие гуманизированный ген фактора активации в-клеток
ES2570962T3 (es) Producción incrementada de un producto diana vía estabilización del ARNm
ES2383716T3 (es) Composiciones y métodos que utilizan ARN de interferencia de un gen del tipo OPR3 para el control de nemátodos
JP2020511131A5 (es)
AR047574A1 (es) Genes del ciclo celular y metodos de uso relacionados
CL2020002973A1 (es) Casetes de expresión de a- glucosidasa de ácido optimizado con codón y métodos de uso del mismo
HUE026630T2 (hu) Eljárás L-triptofán elõállítására javított, Enterobacteriaceae családba tartozó baktériumtörzsek alkalmazásával
RU2015119400A (ru) Средства и методы ферментативного получения l-метионина из о-фосфо-l-гомосерина и метантиола
NZ601950A (en) Method for producing pyripyropene